118 results

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 2/3 300 participants COMPASS Pathways

PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 2/3 105 participants Johns Hopkins University

Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving

Tirzepatide in the Treatment of Cannabis Use Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 15 participants McMaster University

Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 240 participants VA Office of Research and Development

Major Depression

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 172 participants Centre Hospitalier Universitaire de Nīmes

Alcohol Use Disorder, Depressive Sympotoms, Psilocybin

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 2/3 80 participants VA Office of Research and Development

Post Traumatic Stress Disorder, Alcohol Use Disorder

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 31 participants Sunnybrook Health Sciences Centre

Treatment Resistant Depression

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 90 participants Lakshmi N Yatham

Bipolar II Depression

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 60 participants Khyber Medical University Peshawar

Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 160 participants University of Cincinnati

Mild Depression

Sustained Mood Improvement With Laughing Gas Exposure (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 120 participants Women's College Hospital

Major Depressive Disorder, Treatment Resistant Depression

Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 120 participants Bruyère Health Research Institute.

Psychological Distress

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 258 participants Janssen Research & Development, LLC

Depressive Disorder, Major

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 330 participants Cybin IRL Limited

Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series (opens ClinicalTrials.gov in a new tab)

Withdrawn Phase 2/3 0 participants Washington University School of Medicine

Postpartum Depression

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 220 participants Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Depressive Disorder

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 1,254 participants Dr. Inge Winter

Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression

A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 388 participants CSPC Ouyi Pharmaceutical Co., Ltd.

Major Depressive Disorder (MDD)

Understanding and Treating Suicidal Ideation With Ketamine (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 2/3 36 participants The Royal's Institute of Mental Health Research

Suicidal Ideation, Major Depressive Disorder (MDD)

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 400 participants Yale University

Depression

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 200 participants University Hospital, Strasbourg, France

Relapsing-remitting Multiple Sclerosis (RRMS)

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 220 participants Cybin IRL Limited

Major Depressive Disorder

MDMA-assisted Massed Prolonged Exposure for PTSD (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 20 participants Healing Breakthrough

Post-Traumatic Stress Disorder

Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 60 participants Assistance Publique - Hôpitaux de Paris

Major Depressive Episode

Nebulized Ketamine for the Treatment of Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 40 participants Theresa Jacob, PhD, MPH

Severe Depression, Moderate Depression, Ketamine, Midazolam